rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Charles M. Baum

Director

Company insider

Files Form 4 as: Director, Acrivon Therapeutics; Director, PMV Pharmaceuticals; Director, Poseida Therapeutics; Founder, President, and CEO, Mirati Therapeutics; Director, Immunomedics; Director, Array Biopharma.

Every Form 4 they filed

In numbers

Trades disclosed
200
Buys
2
Sells
17
Bought
$226K
Sold
$49.3M
Companies
6
Companies where not an officer
5
First trade
17 Jul 2013
Last trade
17 Jun 2026
Last filed
22 Jun 2026

Companies traded

Where they are an officer
Mirati TherapeuticsDirector, Officer · last 23 Jan 20242 buys · 14 sells
Everywhere else they filed: board seats, 10% stakes, other companies
ACRV Acrivon TherapeuticsDirector · Biotechnology · last 17 Jun 20260 buys · 0 sells
PMVP PMV PharmaceuticalsDirector · Biotechnology · last 4 Jun 20260 buys · 0 sells
Poseida TherapeuticsDirector · last 8 Jan 20250 buys · 0 sells
ImmunomedicsDirector · last 23 Oct 20200 buys · 0 sells
Array BiopharmaDirector · last 30 Jul 20190 buys · 3 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
17 Jun 2026filed 22 Jun 2026ACRV Acrivon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—20,275 at $0.00filing
17 Jun 2026filed 22 Jun 2026ACRV Acrivon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—20,275 at $0.00filing
4 Jun 2026filed 5 Jun 2026PMVP PMV Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—42,000 at $0.00filing
4 Jun 2026filed 5 Jun 2026PMVP PMV Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—42,000 at $0.00filing
18 May 2026filed 20 May 2026ACRV Acrivon TherapeuticsBiotechnologySEC FORM 4 Code A—9,366 at $0.00filing
18 May 2026filed 20 May 2026ACRV Acrivon TherapeuticsBiotechnologySEC FORM 4 Code A—9,366 at $0.00filing
13 Jun 2025filed 17 Jun 2025ACRV Acrivon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—20,275 at $0.00filing
5 Jun 2025filed 9 Jun 2025PMVP PMV Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—33,500 at $0.00filing
8 Jan 2025filed 8 Jan 2025Poseida Therapeuticsoption or derivativeSEC FORM 4 Code D—57,000 at $0.00filing
8 Jan 2025filed 8 Jan 2025Poseida Therapeuticsoption or derivativeSEC FORM 4 Code D—27,350 at $0.00filing
8 Jan 2025filed 8 Jan 2025Poseida Therapeuticsoption or derivativeSEC FORM 4 Code D—27,350 at $0.00filing
8 Jan 2025filed 8 Jan 2025Poseida TherapeuticsSEC FORM 4 Code U—78,600filing
20 Jun 2024filed 24 Jun 2024ACRV Acrivon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—20,275 at $0.00filing
17 Jun 2024filed 18 Jun 2024Poseida Therapeuticsoption or derivativeSEC FORM 4 Code A—27,350 at $0.00filing
17 Jun 2024filed 18 Jun 2024Poseida TherapeuticsSEC FORM 4 Code A—19,650 at $0.00filing
6 Jun 2024filed 10 Jun 2024PMVP PMV Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—67,500 at $0.00filing
23 Jan 2024filed 23 Jan 2024Mirati Therapeuticsoption or derivativeSEC FORM 4 Code D—100,273filing
23 Jan 2024filed 23 Jan 2024Mirati Therapeuticsoption or derivativeSEC FORM 4 Code D—69,258filing
23 Jan 2024filed 23 Jan 2024Mirati Therapeuticsoption or derivativeSEC FORM 4 Code D—81,458filing
23 Jan 2024filed 23 Jan 2024Mirati Therapeuticsoption or derivativeSEC FORM 4 Code D—111,652filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed19

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.